Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

PURPOSE: BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti–programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced non–small-cell lung cancer (NSCLC) across lines of therapy. Patients were selected on the basis of PD-L1 expression on tumor cells (TC) or tumor-in...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:J Clin Oncol
Główni autorzy: Peters, Solange, Gettinger, Scott, Johnson, Melissa L., Jänne, Pasi A., Garassino, Marina C., Christoph, Daniel, Toh, Chee Keong, Rizvi, Naiyer A., Chaft, Jamie E., Carcereny Costa, Enric, Patel, Jyoti D., Chow, Laura Q.M., Koczywas, Marianna, Ho, Cheryl, Früh, Martin, van den Heuvel, Michel, Rothenstein, Jeffrey, Reck, Martin, Paz-Ares, Luis, Shepherd, Frances A., Kurata, Takayasu, Li, Zhengrong, Qiu, Jiaheng, Kowanetz, Marcin, Mocci, Simonetta, Shankar, Geetha, Sandler, Alan, Felip, Enriqueta
Format: Artigo
Język:Inglês
Wydane: American Society of Clinical Oncology 2017
Hasła przedmiotowe:
ORIGINAL REPORTS
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5562171/
https://ncbi.nlm.nih.gov/pubmed/28609226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.71.9476
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy